Skip to main content
SpringerLink
Log in

Target Concentration Strategy for Cyclosporin Monitoring

  • Current Opinion
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The target concentration concept has been proposed as a potential alternative to the established, and probably much abused, therapeutic range method of interpreting concentrations of therapeutic drugs in plasma, serum or blood when individualising drug dosages. This paper raises for debate the possibility of extending this alternative concept to immunosuppressant monitoring with cyclosporin, where there has been considerable difficulty in establishing therapeutic ranges which are widely accepted and applied.

In its broader application, the target concentration strategy does present advantages to the clinician in precision, ability to calculate the dose directly from the target concentration and clearance, as well as a clearer concept of an optimal concentration (differentiating desired and adverse effects).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buchthal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch Neurol 1960; 2: 624–30

    Article  PubMed  CAS  Google Scholar 

  2. Kutt H, Winters W, Kokenge R, et al. Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol 1964; 11: 642–8

    Article  PubMed  CAS  Google Scholar 

  3. Dusci LJ, Hackett P, Chiswell GM, et al. Comparison of cyclosporine in whole blood by high performance liquid chromatography, monoclonal fluorescent polarization immunoassay, and monoclonal enzyme-multiplied immunoassay. Ther Drug Monit 1992; 14: 327–32

    Article  PubMed  CAS  Google Scholar 

  4. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996; 30: 107–40

    Article  PubMed  CAS  Google Scholar 

  5. Shaw LM, Bowers L, Demers L, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine monitoring. Clin Chem 1987; 33: 1268–88

    Google Scholar 

  6. Kahan BD, Shaw LM, Holt D, et al. Consensus document: Hawk’s Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36: 1510–6

    PubMed  CAS  Google Scholar 

  7. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian consensus meeting on cyclosporine monitoring: report of the consensus panel. Clin Chem 1990; 36: 1841–6

    PubMed  CAS  Google Scholar 

  8. Yatscoff RW. Report of the Bureau of Drug Research, Health Protection Branch and Canadian Society of Clinical Biochemists. Clin Biochem 1991; 24: 1–2

    Article  Google Scholar 

  9. Morris RG. Australian cyclosporin therapeutic monitoring survey: 1993. Ther Drug Monit 1994; 16: 564–9

    Article  PubMed  CAS  Google Scholar 

  10. Holt DW, Johnston A, Roberts NB, et al. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 1994; 31: 420–46

    PubMed  Google Scholar 

  11. Oellerich M, Armstrong IVW, Kahan B, et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642–54

    Article  PubMed  CAS  Google Scholar 

  12. Morris RG, Tett SE, Ray JE. Cyclosporin A monitoring in Australia: consensus recommendations. Ther Drug Monit 1994; 16: 570–6

    Article  PubMed  CAS  Google Scholar 

  13. Jones TE, Morris RG. Survey of cyclosporin therapeutic ranges, assay methodology and use of ‘sparing agents’ in Australasian transplant centres. Ther Drug Monit. In press

  14. Shiener LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical pharmacology: basic principles of therapeutics. New York: Macmillan, 1978: 71–109

    Google Scholar 

  15. Holford NHG. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287–91

    Article  PubMed  CAS  Google Scholar 

  16. Holford N, Black P, Couch R, et al. Theophylline target concentration in severe airways obstruction: 10 or 20mg/L? Clin Pharmacokinet 1993; 25: 495–505

    Article  PubMed  CAS  Google Scholar 

  17. Morris RG, Saccoia NC, Ryall RG, et al. Specific EMIT and FPIA assays for cyclosporin compared with Cyclotrac 125IRIA. Ther Drug Monit 1992; 14: 226–33

    Article  PubMed  CAS  Google Scholar 

  18. Johnston A, Holt DW. Concentration-controlled trials. What does the future hold? Clin Pharmacokinet 1995; 28: 93–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville, South Australia, 5011, Australia

    Raymond G. Morris

Authors
  1. Raymond G. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, R.G. Target Concentration Strategy for Cyclosporin Monitoring. Clin-Pharmacokinet 32, 175–179 (1997). https://doi.org/10.2165/00003088-199732030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199732030-00001

Keywords

Search

Navigation